Patient Experience Is Key Element For Oncology Dose Optimization

The push for dose optimization in oncology should incorporate patient experience data, a Friends of Cancer Research White Paper recommends. ‘Tolerability’ is a key element to define in early development, and patient-reported outcomes can help.

Dose optimization
• Source: Shutterstock

Oncology drug developers should gather patient-reported outcomes (PROs) as part of their efforts to optimize dosing in early development, a Friends of Cancer Research white paper recommends.

FOCR released the white paper in conjunction with its annual meeting this month. It was developed by a group...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards